New approaches for precise response evaluation in hepatocellular carcinoma

Table 1 Summary of response criteria

	WHO	RECIST 1.1	EASL	mRECIST
Complete response (CR)	Disappearance of all lesions	Disappearance of all lesions and pathologic lymph nodes	Disappearance of intratumoral areterial enhancement	Disappearance of all lesions and pathologic lymph nodes
Partial response (PR)	≥ 50% decrease in the sum of the area (longest diameters multiplied by longest perpendicular diameters)	≥ 30% decrease in the sum of the longest diameters	≥ 50% decrease in the sum of the arterial enhancing areas (longest diameters multiplied by longest perpendicular diameters)	At least a 30% decrease in the sum of diameters viable (enhancing) target lesions, taking as reference the baseline sum of the target lesions
Stable disease (SD)	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD	Neither PR nor PD
Progressive disease (PD)	≥ 25% increase in the sum of the area	≥ 20% increase in the sum of the longest diameters and ≥ 5 mm absolute increase in the sum of the longest diameters	≥ 25% increase in the size of the arterial enhancing areas or development of a new lesions	≥ 20% increase in the sum of diameters of viable target lesions recorded since treatment started or development of new lesions

WHO: World Health Organization; EASL: European Association for the Study of Liver; mRECIST: Modified Response Evaluation Criteria in Solid Tumors.